NCT06246175View on ClinicalTrials.gov

A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects

PHASE1RecruitingINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions

Type 2 Diabetes

Interventions

DRUG

HRS9531

Receive a single dose of HRS9531 injection

Trial Locations (1)

610000

RECRUITING

Chengdu Xinhua Hospital, Chengdu

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY